News

Granules India announced that the 35th Annual General Meeting(AGM) of the company will be held on 6 August 2026.

Granules India announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 1.75 per equity Share (i.e. 175%) , subject to the approval of the shareholders.

Net profit of Granules India rose 32.59% to Rs 201.57 crore in the quarter ended March 2026 as against Rs 152.03 crore during the previous quarter ended March 2025. Sales rose 21.78% to Rs 1457.43 crore in the quarter ended March 2026 as against Rs 1196.82 crore during the previous quarter ended March 2025.For the full year,net profit rose 18.64% to Rs 595.02 crore in the year ended March 2026 as against Rs 501.52 crore during the previous year ended March 2025. Sales rose 19.81% to Rs 5338.92 crore in the year ended March 2026 as against Rs 4455.97 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1457.431196.82 22 5338.924455.97 20 OPM %24.1621.09 -22.2021.21 - PBDT328.18230.30 43 1091.12854.92 28 PBT246.44166.80 48 794.98629.42 26 NP201.57152.03 33 595.02501.52 19 Powered by Capital Market - Live News

Granules India will hold a meeting of the Board of Directors of the Company on 29 April 2026.

Granules India announced that its US step-down subsidiary, Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc. has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) Status from the US Food and Drug Administration (FDA). The FDA inspection was conducted at the company`s packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility`s second FDA inspection, following the March 2023 audit, which also concluded with zero observations.Powered by Capital Market - Live News